ARS Pharmaceuticals, Inc. filings document the public-company record for a biopharmaceutical issuer commercializing neffy, an epinephrine nasal spray for severe allergic reactions and anaphylaxis. The company’s 8-K filings report financial results, Regulation FD presentation updates, material agreements, product and commercialization disclosures, and legal or regulatory events involving neffy and related patent protections.
ARS Pharmaceuticals’ proxy materials describe board elections, shareholder voting matters, executive compensation, equity awards and audit oversight. Other filings identify its Nasdaq-listed common stock, capital-structure matters, credit arrangements involving ARS Pharmaceuticals Operations, Inc., and risk-related disclosures tied to product development, commercialization, intellectual property and regulatory pathways.
ARS Pharmaceuticals director Peter A. Thompson reported a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.54 per share and expire on June 23, 2036. They vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders. Under an agreement, the economic benefit from any securities issued under these options must be transferred to OrbiMed-related entities.
ARS Pharmaceuticals director Brent L. Saunders received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.54 per share and expire on June 23, 2036. They vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders.
ARS Pharmaceuticals director Phillip M. Schneider received a grant of stock options as compensation. On June 24, 2026, he was awarded options covering 30,000 shares of common stock with an exercise price of $10.54 per share. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting and expire on June 23, 2036. After this grant, Schneider holds 30,000 stock options directly, and the transaction does not involve any open-market buying or selling of shares.
ARS Pharmaceuticals director Laura Shawver received a new stock option grant, not an open-market trade. The Form 4 shows an award of options to acquire 30,000 shares of common stock at an exercise price of $10.54 per share. Following this grant, she holds 30,000 stock options directly. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting, according to the footnote. The options expire on June 23, 2036, giving a long exercise window tied to her board service.
ARS Pharmaceuticals reported results from its 2026 Annual Meeting of Stockholders. As of April 27, 2026, 99,300,658 shares of common stock were outstanding and entitled to vote. Stockholders elected three Class III directors to serve until the 2029 annual meeting.
For the board seats, Saqib Islam received 51,588,419 votes for and 14,429,366 withheld, Phillip Schneider received 38,474,013 for and 27,543,772 withheld, and Laura Shawver received 45,149,811 for and 20,867,974 withheld. Each proposal also recorded 14,111,827 broker non-votes.
Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 79,465,541 votes for, 102,436 against, and 561,635 abstaining. They approved, on an advisory basis, named executive officer compensation and selected an annual frequency for future advisory pay votes.
ARS Pharmaceuticals Chief Commercial Officer Eric Karas exercised stock options and sold shares in a planned transaction. He exercised options to acquire 25,000 shares of common stock at $1.50 per share, then sold 25,000 shares at $10.00 per share in an open-market sale.
The sale was made under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating it was pre-arranged. After these transactions, Karas directly holds 12,176 common shares, which include 1,861 shares acquired through the company’s 2020 Employee Stock Purchase Plan.
ARS Pharmaceuticals Chief Legal Officer Alexander A. Fitzpatrick reported an open-market sale of 3,355 shares of common stock at $10.00 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025 and leaves him holding 90,910 shares directly.
ARS Pharmaceuticals, Inc. filed a Form 3 identifying Donn Casale, the company’s President, as a reporting person for insider holdings. The data show no reported purchases, sales, option exercises, gifts, or other insider transactions associated with this filing.